Income (Loss) Per Common Share (Computation Of Basic And Diluted (Loss) Income Per Common Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended																	12 Months Ended
	Dec. 31, 2019	[1]	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	[1]	Sep. 30, 2017	[1]	Jun. 30, 2017	[1]	Mar. 31, 2017	[1]	Dec. 31, 2019		Dec. 31, 2018		Dec. 31, 2017
Basic (loss) income per common share
Net income (loss)	$ (681)		$ (134)	$ 2,832	$ (297)	$ (776)	$ 1,565	$ 226	$ (3,855)	$ (3,007)		$ 1,325		$ 3,163		$ 2,223		$ 1,720		$ (2,840)		$ 3,704
Net loss (income) allocated to participating securities																		(12)		27		(63)
Net income (loss) allocated to common shareholders																		$ 1,708		$ (2,813)		$ 3,641
Basic weighted-average common shares outstanding																		37,118		36,412		33,008
Basic income (loss) per common share																		$ 0.05		$ (0.08)		$ 0.11
Diluted (loss) income per common share
Net income (loss)	$ (681)		$ (134)	$ 2,832	$ (297)	$ (776)	$ 1,565	$ 226	$ (3,855)	$ (3,007)		$ 1,325		$ 3,163		$ 2,223		$ 1,720		$ (2,840)		$ 3,704
Net (income) loss allocated to participating securities																		(12)		27		(61)
Net income (loss) allocated to common shareholders																		$ 1,708		$ (2,813)		$ 3,643
Basic weighted-average common shares outstanding																		37,118		36,412		33,008
Effect of dilutive stock options and awards																		742				1,155
Diluted weighted-average common shares outstanding																		37,860		36,412		34,163
Diluted income (loss) per common share	$ (0.02)		$ 0.00	$ 0.07	$ (0.01)	$ (0.02)	$ 0.04	$ 0.01	$ (0.11)	$ (0.09)		$ 0.04		$ 0.09		$ 0.06		$ 0.05	[2]	$ (0.08)	[2]	$ 0.11	[2]

[1] In December 2017 we completed our acquisition of JOTEC, which is operated as a wholly-owned subsidiary of CryoLife.

[2] We excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares, because the inclusion of these stock options would be antidilutive to (loss) income per common share. For the year ended December 31, 2018 all stock options and awards were excluded from the calculation of weighted-average common shares outstanding as these would be antidilutive to the net loss. For the years ended December 31, 2019 and 2017 stock options to purchase 131,000 and 227,000 shares, respectively, were excluded from the calculation of diluted weighted-average common shares outstanding.